This is the second published report for the NDTA and contains linked data from the NPDA and NDA for the audit period 2011-12 to 2016-17. The report focuses on young people with Type 1 diabetes (NHS Digital)
Diabetes News
Tag: Type 1 Diabetes
Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide
The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways (Diabetologia)
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes and Glycemic Control over Time: The SEARCH for Diabetes in Youth Study
DKA at T1D diagnosis is associated with worsening glycemic control over time, independent of demographic, socioeconomic and treatment‐related factors and baseline fasting C‐peptide (Peditric Dibetes)
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes
In participants with T1D and T2D, treatment differences (for change in HbA1c and overall hypoglycaemia) between mealtime faster aspart and insulin comparators were similar to the corresponding overall analysis across baseline HbA1c and BMI subgroups. The finding of a lower total daily insulin dose in participants with obesity (BMI > 30 kg/m2) and T1D treated with faster aspart, versus those treated with IAsp, may warrant further investigation (Diabetes Therapy)
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
Empagliflozin on top of metformin treatment significantly improved arterial stiffness compared to metformin in T1DM patients. Endothelial function was similarly improved in all treatment groups (Cardiovascular Diabetology)
Individual glucose responses to prolonged moderate intensity aerobic exercise in adolescents with type 1 diabetes: The higher they start, the harder they fall
Youth with T1D have variable glycemic responses to prolonged aerobic exercise, but this variability is partially explained by their pre‐exercise blood glucose levels. When no implementation strategies are in place to limit the drop in glycemia, the incidence of exercise‐associated hypoglycemia is ~44% and having a high pre‐exercise blood glucose concentration is only marginally protective (Pediatric Diabetes)
Prevalence of Diabetic Neuropathy in Young Adults with Type 1 Diabetes and the Association with Insulin Pump Therapy
DSPN and CAN are prevalent in young adults with T1D with no association found with CSII treatment (Diabetes Technology and Therapeutics)
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
So, is use of SGLTi agents in T1D “an obvious choice,” or are the promises of this approach “too good to be true”? The key lies in precise identification of which patients will obtain the greatest benefit with the least risk (Diabetes Care)
Asymptomatic hypoglycaemia in Type 1 diabetes: incidence and risk factors
Asymptomatic hypoglycaemia constitutes the majority of hypoglycaemic events in Type 1 diabetes. Reduced hypoglycaemia awareness and high insulin dose are risk factors for asymptomatic hypoglycaemia, but other conventional risk factors for severe hypoglycaemia do not correlate with risk of asymptomatic episodes (Diabetic Medicine)
The peripheral atherosclerotic profile in patients with type 1 diabetes mellitus warrants a thorough vascular assessment of asymptomatic patients
Peripheral artery disease is often undiagnosed in asymptomatic patients with DM1. However, its presence may change medical management in a substantial percentage of cases, highlighting the potential benefit of a thorough vascular assessment on these patients (Diabetes/Metabolism Research and Reviews)
Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial
In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy (Diabetes Care)
Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial
CSII has substantial psychosocial benefits. PROs demonstrate these benefits (Pediatric Diabetes)
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD)
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes (The Lancet)
Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark
High gluten intake by mothers during pregnancy could increase the risk of their children developing type 1 diabetes. However, confirmation of these findings are warranted, preferably in an intervention setting (BMJ)
Enteroviral Infections as a Trigger for Type 1 Diabetes
New evidence at the protein, RNA, and host immune response level suggests a role for EV infections in the development of autoimmunity. In the upcoming years, new technologies, collaborative efforts, and therapeutic interventions are likely to find a definitive answer for their role in disease pathogenesis (Current Diabetes Reports)
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
We conclude that using TI appropriately at mealtimes with supplemental dosing improves prandial glucose (TIR and 1–4 h) control without any increase in time in hypoglycemia or weight gain in patients with T1DM on MDI (Diabetes Technology and Therapeutics)
Positive 15-month results with Diamyd® in Type 1 diabetes
When all patients have been followed for 15 months in the diabetes trial DIAGNODE-1, where the diabetes vaccine Diamyd® is given directly into the lymph node, a clearly positive and clinically relevant effect is seen in improving the clinical course and maintaining the endogenous insulin production in newly diagnosed type 1 diabetes (Diamyd Medical)
Biomarkers in Islet Cell Transplantation for Type 1 Diabetes
Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free DNA and circulating miRNA-375 may help predict clinical outcomes (Current Diabetes Reports)
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings
Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus (Annals of Internal Medicine)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »
Glycosmedia is also available as an App: